Mytos Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.77M

  • Investors
  • 26

Mytos General Information

Description

Developer of a fully automated cell manufacturing platform designed to automate human cell production for pharma and biotech businesses. The company's platform uses automation machine technology to configure cell cultures, enabling scientists to make changes to culturing protocols and make quicker advancements in cell growth.

Contact Information

Website
www.mytos.bio
Formerly Known As
Hackscience, Cytera CellWorks
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Translation and Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Other Devices and Supplies
Discovery Tools (Healthcare)
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Translation and Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom

Mytos Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mytos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 19-Dec-2023 $7.77M Completed Generating Revenue
12. Later Stage VC (Series A) 30-Nov-2023 Completed Generating Revenue
11. Seed Round 10-Jul-2020 Completed Product Development
10. Grant 01-Mar-2020 Completed Product Development
9. Seed Round 10-Jan-2019 Completed Product Development
8. Seed Round 20-Jul-2018 Completed Product Development
7. Accelerator/Incubator 01-Jun-2018 Completed Product Development
6. Accelerator/Incubator 12-Mar-2018 Completed Product Development
5. Accelerator/Incubator 11-Jul-2017 $192K $192K Completed Product Development
4. Grant 07-Mar-2017 $15.5K Completed Product Development
To view Mytos’s complete valuation and funding history, request access »

Mytos Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary Shares
A Ordinary
A Ordinary 1,086,600 $0.000000 $0.17 $0.17 1x $0.17 8.67%
To view Mytos’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Mytos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a fully automated cell manufacturing platform designed to automate human cell production for pharma and bio
Biotechnology
London, United Kingdom
41 As of 2025

Bergisch Gladbach, Germany
 

Aubagne, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mytos Competitors (2)

One of Mytos’s 2 competitors is Miltenyi Biotec, a Private Debt Financed company based in Bergisch Gladbach, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Miltenyi Biotec Private Debt Financed Bergisch Gladbach, Germany
Sartorius Stedim Biotech Corporation Aubagne, France
You’re viewing 2 of 2 competitors. Get the full list »

Mytos Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Mytos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230087656-A1 Systems and methods for automated cell culturing Pending 18-Feb-2020
CA-3171351-A1 Systems and methods for automated cell culturing Pending 18-Feb-2020
EP-4107246-A1 Systems and methods for automated cell culturing Pending 18-Feb-2020
US-20210238532-A1 Systems and methods for automated cell culturing Active 19-Aug-2018
US-10988726-B2 Systems and methods for automated cell culturing Active 19-Aug-2018 C12M23/42
To view Mytos’s complete patent history, request access »

Mytos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mytos Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cur8 Capital Venture Capital Minority
Emles Venture Partners Venture Capital Minority
ARTIS Ventures Venture Capital Minority
Buckley Ventures Venture Capital Minority
IQ Capital Partners Venture Capital Minority
You’re viewing 5 of 26 investors. Get the full list »

Ready to get started?

Request a free trial

Mytos FAQs

  • When was Mytos founded?

    Mytos was founded in 2016.

  • Where is Mytos headquartered?

    Mytos is headquartered in London, United Kingdom.

  • What is the size of Mytos?

    Mytos has 41 total employees.

  • What industry is Mytos in?

    Mytos’s primary industry is Biotechnology.

  • Is Mytos a private or public company?

    Mytos is a Private company.

  • What is the current valuation of Mytos?

    The current valuation of Mytos is .

  • What is Mytos’s current revenue?

    The current revenue for Mytos is .

  • How much funding has Mytos raised over time?

    Mytos has raised $29.8M.

  • Who are Mytos’s investors?

    Cur8 Capital, Emles Venture Partners, ARTIS Ventures, Buckley Ventures, and IQ Capital Partners are 5 of 26 investors who have invested in Mytos.

  • Who are Mytos’s competitors?

    Miltenyi Biotec and Sartorius Stedim Biotech are competitors of Mytos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »